Getting Paid for Molecular Tests:
How Clinical Laboratories and Pathology Groups Should Respond to Pre-Authorization Requirements by Payers

PRESS RELEASE

The Dark Report
21806 Briarcliff Dr.
Spicewood, Texas 78669
512-264-7103 o
512-264-0969 f

FOR IMMEDIATE RELEASE

Media Contact: Ron Martin
rbmartin@darkreport.com

Getting Paid for Molecular Tests: How Clinical Laboratories and Pathology Groups Should Respond to Pre-Authorization Requirements by Payers

AUSTIN, Texas (February 1, 2011) — The proliferation of molecular diagnostics is bringing a tidal wave of complexity, cost and quality issues for payers, clinicians and laboratories. As a result, payers are accelerating efforts to appropriately manage the utilization and reimbursement of molecular diagnostics and genetic tests.

To stay ahead of evolving requirements, successful laboratories are deploying technology to collaborate real-time with clinicians, payers and other laboratories. That’s the message in a newly-published White Paper, “Getting Paid for Molecular Tests: How Clinical Laboratories and Pathology Groups Should Respond to Pre-Authorization Requirements by Payers.”

This White Paper is tailored specifically to any laboratory looking to further penetrate their market, increase clinician loyalty and better manage their utilization and relationships with payers. It is published by The Dark Report and Dark Daily http://darkdaily.com/white-papers/getting-paid-for-molecular-tests-how-clinical-laboratories-and-pathology-groups-should-respond-to-pre-authorization-requirements-by-payers and is available free to laboratory professionals as a PDF download.
This educational resource discusses why payer pre-authorization and/or notification for genetic molecular tests will become widespread, the existing differences among payers in pre-authorization of genetic and molecular tests and the advantages of automated payer communication.

A detailed case study reveals how one early adopter replaced its outreach laboratory test ordering with a new system that increased its revenue, decreased the number of claim denials and supported its new billing system.

The paper’s author, Matthew Zubiller, is vice president and general manager of McKesson’s Advanced Diagnostics Management business. Zubiller’s team leads initiatives that advance McKesson’s role in the realm of personalized medicine, genetics and molecular diagnostics.

This White Paper, “Getting Paid for Molecular Tests: How Clinical Laboratories and Pathology Groups Should Respond to Pre-Authorization Requirements by Payers,” is available for free download as a PDF at http://darkdaily.com/white-papers/getting-paid-for-molecular-tests-how-clinical-laboratories-and-pathology-groups-should-respond-to-pre-authorization-requirements-by-payers. It is part of the Dark Daily Resource Center which has a growing library of White Papers and other information resources tailored specifically for the needs of laboratory administrators, lab managers, pathologists and lab industry consultants.

For additional information, Contact:  Ron Martin, 512-264-7103

About The Dark Report

Established in 1995, The Dark Report is the leading source of exclusive business intelligence for laboratory CEOs, COOs, CFOs, Pathologists and Senior industry executives. It is widely-read by leaders in laboratory medicine and diagnostics. The Dark Report produces the famous Executive War College on Laboratory and Pathology Management every spring, which showcases innovations by the nation’s and globe’s leading laboratory organizations. Dark Daily is an Internet-based e-briefing intelligence service, read worldwide by thought leaders in laboratory and pathology management. Other well-known conferences conducted by The Dark Report are Lab Quality Confab (on the use of Lean and Six Sigma methods in labs and hospitals), Molecular Summit (on the integration of in vivo and in vitro diagnostics). The Dark Report co-produces Frontiers in Laboratory Medicine annually in the United Kingdom; Executive Edge bi-annually in Canada; and The Business of Pathology bi-annually in Australia.

-end-